The systemic expansion of a CD4+ CD62Llow CD27- FOXP3- CD44+ CXCR3+ ICOS+ T-bet+ T cell subset in mice treated with anti-cancer cell immunoglobulins was correlated with tumor rejection (68). This evidence concerns the gene CD4 and cancer.